Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

  title={Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures},
  author={Dennis M. Black and Steven R. Cummings and David Brian Karpf and Jane A. Cauley and Desmond E Thompson and Michael C. Nevitt and Doug C. Bauer and Harry K. Genant and William L. Haskell and R Marcus and Susan M. Ott and James C. Torner and Sara A. Quandt and Theodore F. Reiss and Kristine E. Ensrud},
  journal={The Lancet},

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Alendronate effectively reduces fracture risk in postmenopausal women with vertebral fractures and low BMD, including those women at highest risk because of advanced age or severe osteoporosis.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

In women with low BMD but without vertebral fractures, 4 years of alendronate safely increased BMD and decreased the risk of first vertebral deformity.

Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial.

In women with low bone mass who do not meet the bone mineral density criterion for osteoporosis, alendronate is effective in reducing the risk of vertebral fractures.

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial

Among patients who adhere to treatment with alendronate, even those who lose BMD benefit from a substantial reduction in risk of vertebral fracture, and the reduction in bone turnover induced by alendronsate might be more important than BMD changes.

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease.

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.

Women with increases of > or =3% in BMD during the first 1 or 2 years of alendronate treatment had the lowest incidence of new vertebral fractures, suggesting that, among women taking antiresorptive agents, greater increases in B MD are associated with lower risk of new fractures.

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Reductions in fracture risk during treatment with alendronate are consistent in women with existing vertebral fractures and those without such fractures but with bone mineral density in the osteoporotic range.

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.

Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture, and these results highlight the consistent antifracture efficacy of denosumAB in patients with varying degrees of fracture risk.

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.

The early risk reduction for new clinical vertebral fractures with 1 year of raloxifene treatment was similar to that reported with other antiresorptive agents.



Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

Etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content and, after approximately one year of treatment, a significant decrease in the rate of new vertebral fractures.

Pre-existing fractures and bone mass predict vertebral fracture incidence in women.

Combining information about bone mass and prevalent fracture appears to be better for predicting new fractures than either variable alone and Physicians can use these risk factors to identify patients at greatest risk for new fractures.

Treatment of postmenopausal osteoporosis with transdermal estrogen.

Transdermal estradiol treatment is effective in postmenopausal women with established osteoporosis and vertebral fractures and Histomorphometric evaluation of iliac biopsy samples confirmed the effect of estrogen on bone formation rate per bone volume.

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.

It is suggested that, compared with calcium alone, salcatonin given intranasally reduces the rates of fracture by two thirds in elderly women with moderate osteoporosis and increases spinal bone mass in a dose dependent manner.

Epidemiology of vertebral fractures in women.

Vertebral fracture prevalence was assessed in an age-stratified random sample of Rochester, Minnesota women aged 50 years and over, finding that vertebral fractures were common and increased with age.

Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures

  • D. BlackL. Palermo S. Cummings
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1995
It is concluded that use of any of the similar methods, with or without triage, provides a valid approach to defining vertebral deformities.

Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.

The combination of calcium fluoride, and estrogen was more effective than any other combination and grounds for optimism about the efficacy of combinations of available agents with sodium fluoride for fracture in postmenopausal osteoporosis.

Vitamin D3 and calcium to prevent hip fractures in elderly women.

BACKGROUND Hypovitaminosis D and a low calcium intake contribute to increased parathyroid function in elderly persons. Calcium and vitamin D supplements reduce this secondary hyperparathyroidism, but

Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

The hypothesis that postmenopausal use of estrogens protects against subsequent hip fracture in women is supported by this large cohort study of 2873 women in the Framingham Heart Study.